Clinical Trial Update: Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study [NA]

View source ↗

Summary

Pilot study evaluating Lactobacillus casei DG (Enterolactis Plus) for irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Enterolactis Plus (Lactobacillus casei DG)

Snippet

Sponsor: SOFAR S.p.A. | Conditions: Irritable Bowel Syndrome | NA | Status: COMPLETED